MindWalk Holdings (HYFT) EBITDA (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly EBITDA of -$2.3 billion for Q2 2026, down 95.61% year-over-year from -$53.0 billion in Q2 2025, and down 12999563.61% quarter-over-quarter from -$17912.6 in Q1 2026.
Analysis
MindWalk Holdings (HYFT) EBITDA (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported EBITDA for 7 consecutive years, with -$2.3 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA fell 95.61% year-over-year to -$2.3 billion; the TTM figure through Apr 2026 stood at -$2.3 billion (up 50.96% YoY), while the FY2026 annual figure was -$2.3 billion, up 42.98% from the prior year.
- EBITDA declined to -$2.3 billion in Q2 2026 per HYFT's latest filing, from -$17912.6 in the prior quarter.
- Across five years, EBITDA topped out at $16.6 million in Q2 2023 and bottomed at -$3.6 billion in Q3 2024.
- Historically, EBITDA has averaged -$394.0 million across 5 years, with a median of -$1.0 million in 2025.
- Annual changes were most pronounced in 2023 — EBITDA surged 590.74% — and 2024, when it slumped 117339930.13%.
- MindWalk Holdings' EBITDA stood at -$5.89 in 2022, then slumped by 35218.16% to -$2080.5 in 2023, then plunged by 142593.62% to -$3.0 million in 2024, then surged by 32.62% to -$2.0 million in 2025, then sank by 116303.6% to -$2.3 billion in 2026.
- Business Quant data shows HYFT's EBITDA at -$2.3 billion in Q2 2026, -$17912.6 in Q1 2026, and -$2.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | -1.55 Mn |
| 10 | MindWalk Holdings | 61.22 Mn | 52.95 Mn | 1.82 Mn | -2.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -2.33 Mn |
| Jan 31, 2026 | -2.65 Mn |
| Oct 31, 2025 | -2.00 Mn |
| Jul 31, 2025 | -3.03 Mn |
| Apr 30, 2025 | -1.19 Mn |
| Jan 31, 2025 | -17.51 Mn |
| Oct 31, 2024 | -2.97 Mn |
| Jul 31, 2024 | -3.56 Bn |
| Apr 30, 2024 | -16.47 Mn |
| Jan 31, 2024 | -2.47 Mn |
| Oct 31, 2023 | -4.26 Bn |
| Jul 31, 2023 | -5.13 Bn |
| Apr 30, 2023 | -4.49 Mn |
| Jan 31, 2023 | -3.40 Mn |
| Oct 31, 2022 | -5.89 Mn |
| Jul 31, 2022 | -7.81 Mn |
| Apr 30, 2022 | -3.38 Mn |
| Jan 31, 2022 | -2.63 Mn |
| Oct 31, 2021 | -3.56 Mn |
| Jul 31, 2021 | -2.82 Mn |